Developments in Nontuberculous Mycobacterial Infections Pipeline for 2024 [Yahoo! Finance]
MannKind Corporation (MNKD)
Last mannkind corporation earnings: 2/25 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.mannkindcorp.com/press-releases
Company Research
Source: Yahoo! Finance
Nontuberculous Mycobacterial Infections pipeline report offers comprehensive insights into the advancements in treatment options, with over 10 companies and 10 pipeline drugs undergoing clinical development. This marks a significant leap forward in addressing a growing health concern worldwide. Overview of Nontuberculous Mycobacterial Infections Nontuberculous Mycobacterial (NTM) infections are increasingly recognized as significant health issues, particularly in immunocompromised individuals and those with pre-existing lung conditions. The report highlights the complexity of diagnosing and treating NTM infections, which often require prolonged antibiotic therapy and may involve surgical intervention. Pipeline Drug Profiles and Therapeutic Assessment A profound analysis is provided for drugs in various clinical stages including definitive phase III trials, revealing promising therapies with the potential to advance the standard of care for patients with NTM infections. These
Show less
Read more
Impact Snapshot
Event Time:
MNKD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MNKD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MNKD alerts
High impacting MannKind Corporation news events
Weekly update
A roundup of the hottest topics
MNKD
News
- MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease [Yahoo! Finance]Yahoo! Finance
- MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung DiseaseGlobeNewswire
- MannKind to Present at 2024 Cantor Fitzgerald Global Healthcare ConferenceGlobeNewswire
- MannKind Co. (NASDAQ: MNKD) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.MarketBeat
- MannKind Co. (NASDAQ: MNKD) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $8.00 price target on the stock.MarketBeat
MNKD
Earnings
- 8/7/24 - Beat
MNKD
Sec Filings
- 9/4/24 - Form 4
- 9/3/24 - Form 144
- 8/30/24 - Form 4
- MNKD's page on the SEC website